Advertisement
Table 2 Orally administered anti-diabetic drugs (OAD) and insulin at baseline and the end of the monitoring period
| Control group | Active group | p-value | |
|---|---|---|---|
| Start of the monitoring period n (%) or mean value ± SD | |||
| Metformin | 71 (44.7) | 64 (45.1) | 0.942 |
| Sulfonylureas | 15 (9.4) | 14 (9.9) | 0.901 |
| Meglitinides (repaglinide/nateglinide) | 0 (0.0) | 0 (0.0) | - |
| Thiazolidinedions | 3 (1.9) | 10 (7.0) | 0.028 |
| Alpha-glucosidase inhibitor | 2 (1.3) | 1 (0.7) | 1.0 |
| Other* | 1 (0.6) | 0 (0.0) | 1.0 |
| Biphasic human insulin (U/day) | 47.84 ± 20.05 | 44.75 ± 19.85 | 0.18 |
| Biphasic human insulin (U/kg/day) | 0.61 ± 0.27 | 0.56 ± 0.25 | 0.13 |
| End of the monitoring period n (%) | |||
| Metformin | 63(39.6) | 62 (43.7) | 0.478 |
| Sulfonylurea | 2 (1.3) | 18 (12.7) | <0.001 |
| Meglitinides (repaglinide/nateglinide) | 0 (0.0) | 6 (4.2) | 0.009 |
| Thiazolidinedions | 1 (0.6) | 7 (4.9) | 0.021 |
| Alpha-glucosidase inhibitor | 1 (0.6) | 1 (0.7) | 1.0 |
| Other* | 1 (0.6) | 2 (1.4) | 0.604 |
| Total insulin (glargine or biphasic plus prandial) dose (U/day) | 50.89 ± 21.56 | 42.97 ± 21.53 | <0.001 |
| Total insulin (glargine or biphasic plus prandial) dose (U/kg/day) | 0.65 ± 0.28 | 0.53 ± 0.26 | <0.001 |
| Change [%, 95% confidence intervals, (CI)] in the OAD and daily insulin dose between baseline and the end of the monitoring period | |||
| %, 95% CI | %, 95% CI | ||
| Metformin | -5.0 (-9.5, -0.4) | -1.4 (-6.6, 3.8) | |
| p-value (baseline vs end) | 0.033 | 0.593 | |
| Sulfonylureas | -8.1 (-12.9, 0.4) | 2.8 (-3.9, 3.8) | |
| p-value (baseline vs end) | 0.001 | 0.393 | |
| Meglitinides (repaglinide/nateglinide) | 0.0 | 4.2 (0.8, 7.6) | |
| p-value (baseline vs end) | - | 0.014 | |
| Thiazolinidiones | -1.3 (-3.0, 0.5) | -2.1 (-5.2, 1.0) | |
| p-value (baseline vs end) | 0.157 | 0.180 | |
| Alpha-glusidase inhibitor | 0.0 | 0.0 | |
| p-value (baseline vs end) | 0.317 | - | |
| Other* | 0.0 (-1.7, 1.7) | 1.4 (-0.5, 3.4) | |
| p-value (baseline vs end) | 1.0 | 0.157 | |
| Total insulin (glargine or biphasic plus prandial) dose (U/day) | 3.49 (2.16, 4.82) | -1.78 (-5.25, -1.69) | |
| p-value (baseline vs end) | <0.001 | 0.01 | |
| Total insulin (glargine or biphasic plus prandial) dose (U/kg/day) | 0.04 (0.02, 0.06) | -0.02 (-0.07, -0.01) | |
| p-value (baseline vs end) | <0.001 | 0.007 | |
